Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 5

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) General Information

Description

An oral therapy approved in 51 countries worldwide, including member states of the European Union and the USA. The medication is for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) to reduce blood Phe levels in patients. It is a pharmaceutical formulation of BH4, the natural cofactor for the PAH enzyme, which stimulates activity of the residual PAH enzyme to metabolize Phe into tyrosine. It is to be used in conjunction with a Phe-restricted diet.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Darmstadt
  • Germany
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Other Business Products and Services
Acquirer
BioMarin Pharmaceutical
Vertical(s)
Life Sciences
Corporate Office
  • Darmstadt
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request a free trial

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request a free trial

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) FAQs

  • Where is Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) headquartered?

    Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) is headquartered in Darmstadt, Germany.

  • What industry is Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) in?

    Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)’s primary industry is Buildings and Property.

  • Is Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) a private or public company?

    Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) is a Private company.

  • What is the current valuation of Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)?

    The current valuation of Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) is .

  • What is Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)’s current revenue?

    The current revenue for Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) is .

  • Who are Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)’s investors?

    Merck Biopharma has invested in Merck Serono & BioMarin Pharmaceutical (Kuvan Rights).

  • When was Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) acquired?

    Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) was acquired on 01-Oct-2015.

  • Who acquired Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)?

    Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) was acquired by BioMarin Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »